The International SubcutaneouS Implantable Cardioverter Defibrillator Registry (iSuSI)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorUniversity of Luebeck

About this trial

The entirely subcutaneous implantable defibrillator (S-ICD) (Emblem, Boston Scientific, Marlborough, MA, USA) was introduced as a new therapeutic alternative to the conventional transvenous ICD in 2009 and implantations are rapidly expanding since then.1 Implantation of the S-ICD seems to reduce implant-related perioperative complications such as pneumothorax, hematoma and cardiac tamponade.

The aim of this multicenter registry is thus to assess the outcome of patients following an S-ICD implantation in a real-world setting.

Eligibility criteria

Qualifiers

Implantation of an S-ICD, regardless of the technique

At least 1 month of follow up

At least 1 post-implantation assessment, in accordance to the routine clinical practice of every center (e.g. in person visit or remote follow up)

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

University of Luebeck

Lead sponsor

Prof. Jürgen Kuschyk, M.D

Collaborator

Giovanni Forleo, M.D.

Collaborator

Mauro Biffi, M.D.

Collaborator